冷静脉液体诱导目标温度管理:TTH48试验亚组研究
该研究为TTH48试验的事后亚组分析,纳入352例院外心脏骤停患者,其中110例在ICU前接受冷静脉液体降温。主要终点为达到目标温度(<34°C)的时间,预设1小时差异有临床意义。结果显示,冷液体组达到目标温度的时间并未缩短(标准化β系数0.06,95%CI -49至16,p=0.32),且两组在缺氧、电解质异常及院内死亡率方面无显著差异。结论认为,ICU前使用冷静脉液体启动TTM未能减少达到目标温度的时间。
要点
- 在352例院外心脏骤停患者中,110例接受ICU前冷静脉液体降温,并未缩短达到目标温度(<34°C)的时间(标准化β系数0.06,95%CI -49至16,p=0.32)。
- 冷液体组从ROSC到达到目标温度的中位时间反而更长(318 vs. 281 min,p<0.01),但多因素回归后无显著关联。
- 两组入ICU时缺氧发生率(1.8% vs. 3.3%,p=0.43)及电解质异常(低钠血症1.8% vs. 2.9%,p=0.54;低钾血症1.8% vs. 4.5%,p=0.20)无显著差异。
- 两组院内死亡率无显著差异。
- 该研究提示,ICU前冷静脉液体降温未能有效缩短达到目标温度的时间,且未增加副作用。
适用人群与场景
- TTH48试验中纳入的院外心脏骤停(OHCA)患者,亚组分析n=352,其中110例接受ICU前冷静脉液体降温。
研究设计与关键结果
- 研究类型:TTH48试验(NCT01689077)的事后亚组分析,样本量352例,其中110例接受ICU前冷静脉液体降温。
- 主要终点:达到目标温度(<34°C)的时间(TTT),预设1小时差异有临床意义;冷液体组与未冷液体组TTT无显著差异(标准化β系数0.06,95%CI for B -49至16,p=0.32)。
- 次要终点:入ICU时缺氧发生率冷液体组1.8% vs. 未冷液体组3.3%(p=0.43);低钠血症1.8% vs. 2.9%(p=0.54);低钾血症1.8% vs. 4.5%(p=0.20);院内死亡率两组无显著差异。
- 冷液体组从ROSC到TTT的中位时间较未冷液体组长(318 vs. 281 min,p<0.01)。
证据类型、等级与局限
- 证据类型:TTH48试验的事后亚组分析(post hoc analysis)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,ICU前使用冷静脉液体启动TTM未能缩短达到目标温度的时间,且未显著增加副作用或改善死亡率。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Pre-intensive care unit (ICU) induction of targeted temperature management (TTM) with cold intravenous (i.v.) fluids does not appear to improve outcomes after in out-of-hospital cardiac arrest (OHCA). We hypothesized that this may be due to ineffective cooling and side effects.
METHODS: A post hoc analysis of a sub-group of patients (n = 352) in the TTH48 trial (NCT01689077) who received or did not receive pre-ICU cooling using cold i.v. fluids. Data collection included patient characteristics, cardiac arrest factors, cooling methods, side effects and continuous core temperature measurements. The primary endpoint was the time to target temperature (TTT, <34 °C), and the secondary endpoints included the incidence of circulatory side effects, abnormal electrolyte levels and hypoxia within the first 24 h of ICU care. A difference of 1 h in the TTT was determined as clinically significant a priori.
RESULTS: Of 352 patients included in the present analysis, 110 received pre-ICU cold fluids. The median time to the return of spontaneous circulation (ROSC) and TTT in the pre-ICU cold fluids group was longer than that of the group that did not receive pre-ICU cold fluids (318 vs. 281 min, p < 0.01). In a linear regression model including the treatment centre, body mass index (BMI), chronic heart failure, diabetes mellitus and time to ROSC, the use of pre-ICU cold i.v. fluids was not associated with a shorter time to the target temperature (standardized beta coefficient: 0.06, 95% CI for B -49 and 16, p = 0.32). According to the receipt or not of pre-ICU cold i.v. fluids, there was no difference in the proportion of patients with hypoxia on ICU admission (1.8% vs. 3.3%, p = 0.43) or the proportion of patients with electrolyte abnormalities (hyponatremia: 1.8% vs. 2.9% p = 0.54; hypokalaemia: 1.8% vs. 4.5%, p = 0.20). Furthermore, there was no difference in hospital mortality between the groups.
CONCLUSIONS: The initiation of TTM with cold i.v. fluids before ICU arrival did not decrease the TTT. We detected no significant between-group difference in mortality or the incidence of side effects according to the administration or not of pre-ICU cold i.v fluids.
参考来源
- Holm A, Kirkegaard H, Taccone F, et al. Cold fluids for induction of targeted temperature management: A sub-study of the TTH48 trial. Resuscitation. 2020. PMID: 31962179. doi:10.1016/j.resuscitation.2019.11.031
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。